A Comparison of an Atypical and Typical Antipsychotic, Zotepine Versus Haloperidol in Patients with Acute Exacerbation of Schizophrenia: A Parallel-Group Double-Blind Trial

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 81-87

  Petit, Michel ^a   Raniwalla, Joher ^b   Tweed, Jack ^b   Leutenegger, Eric ^c   Dollfus, Sonia ^d   Kelly, Finian ^b  

^a UNIVERSITÉ DE ROUEN   (France)

^b ABBOTT LABORATORIES   (United States)

^c Laboratoires Knoll France SA   (France)

^d CHU   (France)

Author keywords

Antipsychotic; Atypical; Haloperidol; Schizophrenia; Zotepine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HALOPERIDOL; URIC ACID; ZOTEPINE;

ADULT; AKATHISIA; AKINESIA; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOURICEMIA; INSOMNIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DIBENZOTHIEPINS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0029889665     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3d ed., revised. Washington, DC: The Association, 1987.
2. Andreasen, NC. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundation. Br. J. Psychiatry 155(Suppl. 7):49-58, 1989.
3. Angrist, B; Rotrosen, J; and Gershon, S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72:17-19, 1980.
4. Barnas, C; Stuppäck, CH; Miller, C; Haring, C; Sperner-Unterweger, B; and Fleischhacker, WW. Zotepine in the treatment of schizophrenic patients with prevailingly nega-tive symptoms. A double-blind trial vs. haloperidol. Int. Clin. Psychopharmacol. 7:23-27, 1992.
5. Borison, RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J. Clin. Psychopharmacol. 15 (Suppl.):24S-29S, 1995.
6. Crow, TJ. Molecular pathology of schizophrenia: More than one disease process? Br. Med. J. 280:66-68, 1980.
7. Data on file. Zotepine (Investigators brochure). July 14, 1994. Nottingham, UK: Knoll Pharmaceuticals.
8. Feighner, JP, and Boyer, WF. Selective Serotonin Re-uptake Inhibitors: Perspectives In Psychiatry. New York: John Wiley and Sons, 1991. pp. 89-132.
9. Fleischhacker, WW; Barnas, C; Stuppäck, CH; Unterweger, B; Miller, C; and Hinterhuber, H. Zotepine vs. haloperidol inparanoid schizophrenia: A double-blind trial. Psychopharmacol. Bull. 25:97-100, 1989.
10. Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Insitute of Mental Health, 1976. pp. 218-222.
11. Kane, J; Honigfeld, G; Singer, J; and Meltzer, H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45:789-796, 1988.
12. Kane, JM. Treatment of schizophrenia. Schizophr. Bull. 13:133-156, 1987.
13. Kay, SR, and Singh, MM. The positive-negative distinction in drug-free schizophrenic patients: Stability, response to neuroleptics, and prognostic significance. Arch. Gen. Psychiatry 46:711-718, 1989.
14. Leysen, JE; Janssen, PMF; Schotte, A; Luyten, WHML; and Megens, AAHP. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors. Psychopharmacology 112:S40-S54, 1993.
15. Meltzer, HY. Dimensions of outcome with clozapine. Br. J. Psychiatry 160 (Suppl.):46-53, 1992.
16. Necdham, PL; Atkinson, J; Skill, MJ; and Heal, DJ. Zotepine: Preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol. Bull. 31(1):123-128, 1996.
17. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
18. Overall, JE, and Gorham, DR. The brief psychiatric rating scale. Psychol. Rep. 10:799-812, 1962.
19. Overall, JE. and Gorham, DR. Introduction - The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol. Bull. 24:97-99, 1988.
20. Roth, BL; Craigo, SC; Choudhary, MS; Uluer, A; Monsma, FJ; Shen, Y; Meltzer, HY; and Sibley, DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268:1403-1409, 1994.
21. SAS Institute, Inc. SAS User's Guide, Version 6.08. Cary, NC: SAS Institute, Inc.
22. Simpson, GM, and Angus, JSW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 45 (Suppl.): 11-19, 1970.
23. Van Putten, T, and Marder, SR. Behavioural toxicity of antipsychotic drugs. J. Clin. Psychiatry 48 (Suppl.): 13-19, 1987.